
New research reveals collagen mimetic peptides may effectively restore ocular tissue stiffness, offering hope for myopia and other eye diseases.

New research reveals collagen mimetic peptides may effectively restore ocular tissue stiffness, offering hope for myopia and other eye diseases.

Ophthalmologists report high satisfaction with lifitegrast for dry eye treatment, noting rapid symptom relief and effective management in diverse patient populations.

The bill will make 3 changes that enhance oral medication usage, with 1 change expanding access to in-office procedures.

Catch up on the top stories in optometry during the week of July 14-July 18.

Nicox’s nitric oxide (NO)-donating bimatoprost eye drop works to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Study authors Preeya K. Gupta, MD; and Paul Karpecki, OD, formulated a case in their literature review for the routine evaluation of the upper eyelid during meibomian gland imaging.

ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.

A Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025, was assigned by the FDA.

These screening solutions will work to make early detection of diabetic retinopathy easier with on-the-spot screening.

A recent study reveals that ADHD in schoolchildren correlates with lower myopia prevalence and shorter eye length, suggesting intriguing links between vision and attention disorders.

The Topical Sustain Release drop technology was designed to address suboptimal patient adherence and high treatment cost.

Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.

The primary study outcomes were the cumulative incidence rate of myopia, with myopia defined as an SER −0.50 diopter (D) or less and the percentage of participants who had a fast myopic shift that was defined as a spherical equivalent myopic shift of 0.50 D or greater over the course of 1 year.

Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.

Joe Shovlin, OD, FAAO, sat down with Optometry Times to detail a presentation he gave at AOA's Optometry's Meeting 2025.

A study reveals that secondhand smoke significantly increases the risk of myopia in Chinese children, highlighting the need for smoke-free environments.

From blue light blockers to sleep apnea, Jacqueline Theis, OD, FAAO, FNAP; and Joseph Allen, OD, FAAO, Dipl ABO, outlined how sleep can influence brain and ocular health, and vice versa.

The DSLT technology has been fully commercially available in the US since February 2025.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Catch up on the top stories in optometry during the week of July 7-July 11.

Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.

Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.

A total of 20 countries will have import duties due and reciprocal tariffs will be in effect starting August 1.

Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.

Explaining how different examinations are billed by insurance to patients can make a difference in patient care.

Beginning in July 21, the Varilux Physio extensee and Varilux Physio extensee Classic Edition will be available in the US.

Kristin Adams, OD, and Colleen Onstad, MSW, LICSW, detailed the importance of recognizing the signs of domestic violence in patients during Optometry's Meeting 2025.

Carlos Chacon, OD, MSc, FIACLE, cited economic and geographic barriers and nonstandardized education as the major barriers keeping patients from adequate eye care in Latin America.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared with baseline for people living with early to intermediate dry AMD.

Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.